TIDMBSFA
RNS Number : 6769L
BSF Enterprise PLC
17 May 2022
17 May 2022
BSF Enterprise PLC
("BSF" or "the Company")
Admission to Trading and First Day of Dealings
Following the successful reverse takeover of 3D Bio-Tissues
Limited ("3DBT"), a tissue engineering business based in Newcastle,
UK, the Company announces admission of the enlarged group to the
standard segment of the Official List and initiation of trading on
the London Stock Exchange's Main Market at 8.00 a.m. today under
the ticker ' BSFA ' ("Admission"). The Admission follows a placing
which raised GBP1.75m at a placing price of 7.37 pence per
share.
About 3DBT
-- A tissue engineering company with patent-protected IP that is
already producing human corneas that could help restore vision to
millions of people
-- It has three strands of IP, each with a different sector
focus, development and revenue timeline:
-- Serum-free media: 3DBT's City-mix(TM) is an animal-free cell
growth agent for culturing skin, muscle & fat cells which will
be used for lab-grown meat and leather production
-- Skin Care Products: Lipopeptide Etsyl(TM) actively increases
collagen production in human skin cells which can be used in
cosmetic and skin care products
-- Tissue Templating Application: using a platform to grow
different tissues with natural structure & function such as
corneas, lab-grown meat and leather & human skin
substitutes
-- Building on its success to date, 3DBT is focused on producing
the UK's first 100% lab-grown meat in the next 12 months
-- The funds raised will be used to expand the team and to
market the Company's animal-free cell growth agent (serum free
media) and cosmetics
-- Strong management team with over 20 years' experience in
extracellular matrix biology and tissue engineering - globally
recognised experts in molecular biology
About BSF
-- Aim to accelerate the tissue engineering sector, which
includes the growth of cell-laden structures including production
of high quality, lab-grown meat and leather
-- Experienced Board with a clear strategy - acquire, develop
and license technology in cultured animal tissue and related
products
-- Operating in fast growing and transformative markets - 410%
CAGR (2021 to 2030) for lab-grown meat; 12.7m people currently
awaiting cornea transplant.
Geoff Baker, Executive Director of BSF, commented:
"Our successful acquisition of 3DBT provides investors with
exposure to an extremely exciting suite of IP which can be used for
multiple applications across numerous fast-growing and
transformative markets, including the lab grown meat and leather
markets, as well as skin care.
"The skilled 3DBT team has already produced the world's first
human corneas, which is a fantastic feat given that 12.7m people
worldwide are currently awaiting a cornea transplant.
"Together, we are now focused on building on this success,
creating value by executing on the different verticals that our
technology can be applied to. The market for lab-grown meat - which
is expected to grow at a CAGR of 410% to 2030 - is just one of
these, and our aim to produce the UK's first cut of cultured meat
in the next 12 months is expected to open doors to potential
customers in the food supply chain. Importantly, demand for
high-quality alternative protein sources is high, driven by the
critical need to reduce global greenhouse gases, for which
livestock farming is responsible for a staggering 24%.
"Our technology has the potential to improve the lives of
millions of people around the world, and we would like to take this
opportunity to thank our investors for their support in delivering
this exciting milestone."
For further enquiries, please visit www.bsfenterprise.com or
contact:
BSF Enterprise PLC Via SEC Newgate
below
Geoff Baker - Non-Executive Director
Che Connon - Executive Director
Shard Capital (Broker)
Damon Heath 0203 971 7000
SEC Newgate (Financial Communications)
Bob Huxford 020 3757 6882
Elisabeth Cowell BSF@secnewgate.co.uk
George Esmond
ISIN of the Ordinary Shares is GB00BHNBDQ51
SEDOL Code is BHNBDQ5 .
Notes to Editors
BSF Enterprise PLC (BSF) is focused on unlocking the next
generation of biotechnological solutions - using cell-based tissue
engineering to help generate cultured meat, lab-grown leather, as
well as human corneas, collagen growth and skin substitutes, as
part of a radical transformation to deliver sustainable solutions
across a variety of sectors.
It owns 100% of 3D Bio Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help
restore vision to millions of people. Building on this success, it
aims to produce the UK's first high quality lab-grown meat from its
laboratory in Newcastle the next 12 months, transforming the
meat-production industry towards an ethical and sustainable
practice.
BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as
well as through M&A. It aims to acquire a suite of technologies
that underpins the development of tissue templating for corneas,
meat and leather, and license out the IP to manufacturers,
wholesalers and distributors to help manufacture the products at
scale.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFLREDIRLIF
(END) Dow Jones Newswires
May 17, 2022 11:02 ET (15:02 GMT)
Bsf Enterprise (LSE:BSFA)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Bsf Enterprise (LSE:BSFA)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
